NCT05219422 Testing ALERT With GTO in Middle Schools
| NCT ID | NCT05219422 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RAND |
| Condition | Substance Abuse |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2022-08-30 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2022-08-30 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To test the efficacy of Project ALERT with the support enhancement tool, Getting To Outcomes.
Eligibility Criteria
Inclusion Criteria: * Eligibility for student participants: all students in 7th grade, primarily aged 12-14, attending school at one of the enrolled schools in the study. * Eligibility for school staff participants: all educators interested in enrolling in the study at each of the enrolled schools. Exclusion Criteria: * Not meeting eligibility criteria Note: the age range is from 11 to 70 to account for both the student AND teacher populations.
Contact & Investigator
Matthew Chinman, PhD
PRINCIPAL INVESTIGATOR
RAND
Frequently Asked Questions
Who can join the NCT05219422 clinical trial?
This trial is open to participants of all sexes, aged 11 Years or older, up to 70 Years, studying Substance Abuse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05219422 currently recruiting?
Yes, NCT05219422 is actively recruiting participants. Contact the research team at chinman@rand.org for enrollment information.
Where is the NCT05219422 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT05219422 clinical trial?
NCT05219422 is sponsored by RAND. The principal investigator is Matthew Chinman, PhD at RAND. The trial plans to enroll 42 participants.